Search research articles
Contact Us
Filters
Showing results (121-130 of 211) with videos related to
Page
of 22
Sort By:
The Lancet. Oncology
|
April 5, 2017
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L Gulley, Arun Rajan, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Funda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney, et al.
BMJ Open
|
September 14, 2022
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
Daniel J George, David R Spigel, Lucio N Gordan, et al.
Molecular Cancer Therapeutics
|
June 9, 2012
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors
Howard A Burris, Afshin Dowlati, Rebecca A Moss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
Suresh S Ramalingam, David R Spigel, David Chen, et al.
The Lancet. Oncology
|
January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Toni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
Clinical Lung Cancer
|
December 18, 2014
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer
Craig H Reynolds, Jyoti D Patel, Edward B Garon, et al.
Clinical Lung Cancer
|
September 24, 2005
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial
David R Spigel, John D Hainsworth, Emily R Burkett, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 7, 2020
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Corinne Faivre-Finn, David R Spigel, Suresh Senan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 8, 2025
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial
Yuanyuan Zhang, Aaron M Laine, Puneeth Iyengar, et al.
Page
of 22
Search research articles
Search
Showing results (121-130 of 211) with videos related to
Sort By:
Page
of 22
The Lancet. Oncology
|
April 5, 2017
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
James L Gulley, Arun Rajan, David R Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Funda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney, et al.
BMJ Open
|
September 14, 2022
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
Daniel J George, David R Spigel, Lucio N Gordan, et al.
Molecular Cancer Therapeutics
|
June 9, 2012
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors
Howard A Burris, Afshin Dowlati, Rebecca A Moss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2011
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
Suresh S Ramalingam, David R Spigel, David Chen, et al.
The Lancet. Oncology
|
January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Toni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
Clinical Lung Cancer
|
December 18, 2014
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer
Craig H Reynolds, Jyoti D Patel, Edward B Garon, et al.
Clinical Lung Cancer
|
September 24, 2005
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial
David R Spigel, John D Hainsworth, Emily R Burkett, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 7, 2020
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Corinne Faivre-Finn, David R Spigel, Suresh Senan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 8, 2025
Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial
Yuanyuan Zhang, Aaron M Laine, Puneeth Iyengar, et al.
Page
of 22